Weekly nanoparticle albumin bound-paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma

Abstract

ObjectiveMore effective regimens for advanced esophageal squamous cell carcinoma (ESCC) are urgently needed. Therefore, a retrospective study concerning the efficacy and safety of nanoparticle albumin-bound paclitaxel plus cisplatin (nab-TP) versus solvent-based paclitaxel plus cisplatin (sb-TP) as a first-line therapy was conducted in Chinese patients with advanced ESCC.MethodsFrom June 2009 to June 2015, 32 patients were treated with nab-paclitaxel (125 mg/m2) on the first and eighth days (30 minutes infusion) and cisplatin (75 mg/m2) on the second day every 21 days (nab-TP arm). Also, 43 patients were treated with solvent-based paclitaxel (80 mg/m2) intravenously on the first and eighth days and the same dose of cisplatin (sb-TP arm). The two groups were compared in terms of objective response rate (ORR), disease control rate, progression-free survival (PFS), overall survival (OS), and safety profile. OS and PFS were estimated using Kaplan–Meier methods to determine associations between chemotherapy regimens and survival outcomes.ResultsNab-TP demonstrated a higher ORR (50% vs 30%; P=0.082) and disease control rate (81% vs 65%; P=0.124) than sb-TP. Median OS was similar for nab-TP and sb-TP (12.5 vs 10.7 months; P=0.269). However, nab-TP resulted in a longer median PFS (6.1 months [95% confidence interval: 5.3–6.9]) than sb-TP (5.0 months [95% confidence interval: 4.4–5.6]) (P=0.029). The most common adverse events included anemia, leukopenia, neutropenia, febrile neutropenia, and thrombocytopenia in both the groups and no statistically significant differences were observed between the groups. With statistically significant differences, significantly less grade ≥3 peripheral neuropathy, arthralgia, and myalgia occurred in the nab-TP arm (all P<0.05). Dose reduction, treatment delays, and second-line therapy were similar between the two regimens. There were no treatment-related deaths in either group.ConclusionNab-paclitaxel plus cisplatin is found to be an effective and tolerable option for advanced ESCC in the People’s Republic of China.

Synergistic effect of Abraxane that combines human IL15 fused with an albumin‐binding domain on murine models of pancreatic ductal adenocarcinoma

“…Abraxane is a unique nanoparticle of an albumin‐bound form of paclitaxel, which has a higher response rate and enhanced safety profiles compared to a solvent‐based formulation of paclitaxel. 18 , 19 Abraxane is associated with a prolonged half‐life, increased accumulation in the tumour, macropinocytosis‐driven activation of macrophages, apoptosis of cancer cells and improved accessibility for immune cells and therapeutics to the TME through stromal depletion. 20 The treatment of Abraxane combined with gemcitabine was granted FDA approval in 2013 for patients with late‐stage pancreatic cancer, based on the results of a phase III randomized trial, which demonstrated that Abraxane/gemcitabine provides a significantly improved median overall survival of 8.5 months, compared to 6.7 months for gemcitabine alone.…”

“…However, the serious adverse effects mean that FOLFIRINOX is only suitable for PDAC patients with a relatively good performance status. Abraxane is a unique nanoparticle of an albumin‐bound form of paclitaxel, which has a higher response rate and enhanced safety profiles compared to a solvent‐based formulation of paclitaxel 18,19 . Abraxane is associated with a prolonged half‐life, increased accumulation in the tumour, macropinocytosis‐driven activation of macrophages, apoptosis of cancer cells and improved accessibility for immune cells and therapeutics to the TME through stromal depletion 20 .…”

Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

“…Wang et al [ 13 ] demonstrated that weekly nab-paclitaxel plus cisplatin with concurrent definitive radiotherapy is an effective and well-tolerated treatment option for ESCC. In addition, Wang et al [ 14 ] compared the values of nanoparticle albumin-bound paclitaxel plus cisplatin (nab-TP) vs solvent-based paclitaxel plus cisplatin (sb-TP) and found that nab-TP demonstrated a higher ORR (50% vs 30%, P = 0.082) and disease control rate (81% vs 65%, P = 0.124) than sb-TP, as well as a longer median PFS (6.1 mo, 95%CI: 5.3-6.9) ( P = 0.029). In contrast, LBP used in our current study is a new-generation platinum drug.…”

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma

“… 21 , 22 , 23 , 24 , 25 Particularly for advanced ESCC cases, nabTP as a first‐line therapy may improve survival with an increased response rate. 26 In addition, nab‐paclitaxel based neoadjuvant chemotherapy has been shown to produce positive results for locally advanced ESCC. 27 Nevertheless, the comparison of nabTP‐ICIs and TP‐ICIs schemes is still lacking.…”